A Lung Cancer Patient Harboring a Rare Oncogenic EGFR Exon 20 V786M Mutation Responded to a Third-Generation Tyrosine Kinase Inhibitor: Case Report and Review of the Literature.

导出 LinkOut

翻译打印收藏纠错

作者： Qi,Zhu ^[1] ; Mingyun,Jiang ^[2] ; Wenfei,Li ^[3] ; Shuangli,Sun ^[3] ; Jisheng,Li ^[4] ; Justin,Stebbing ^[5] ; Xiaodong,Liang ^[2] ; Ling,Peng ^[6]

作者单位： Cancer Center, Department of Pulmonary and Critical Care Medicine, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, China. ^[1] Graduate Department, Bengbu Medical College, Bengbu, China. ^[2] Department of Biochemistry & Molecular Biology, Shandong University, Jinan, China. ^[3] Department of Medical Oncology, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China. ^[4] Division of Cancer, Department of Surgery and Cancer, Imperial College London, London, United Kingdom. ^[5] Cancer Center, Department of Radiation Oncology, Zhejiang Provincial People's Hospital, Affiliated People's Hospital, Hangzhou Medical College, Hangzhou, China. ^[6]

关键词 EGFR NSCLC immune checkpoint inhibitor rare mutation tyrosine kinase inhibitor

DOI 10.3389/fonc.2022.912426

PMID 35664749

发布时间 2022-07-16

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Frontiers in oncology

2022年12卷

912426页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

A Lung Cancer Patient Harboring a Rare Oncogenic EGFR Exon 20 V786M Mutation Responded to a Third-Generation Tyrosine Kinase Inhibitor: Case Report and Review of the Literature.

Frontiers in oncology

相似文献

Frontiers in oncology

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

A Lung Cancer Patient Harboring a Rare Oncogenic EGFR Exon 20 V786M Mutation Responded to a Third-Generation Tyrosine Kinase Inhibitor: Case Report and Review of the Literature.

Frontiers in oncology

相似文献

Frontiers in oncology

相关期刊

检索历史清除